An open-label study to assess the feasibility and tolerability of rilmenidine for the treatment of Huntington’s disease
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Neurology"
DOI: 10.1007/s00415-017-8647-0
Abstract: AbstractPreclinical data have shown that rilmenidine can regulate autophagy in models of Huntington’s disease (HD), providing a potential route to alter the disease course in patients. Consequently, a 2-year open-label study examining the tolerability and… read more here.
Keywords: huntington disease; disease; study; open label ... See more keywords
A phase 2, open-label study of brentuximab vedotin in patients with CD30-expressing solid tumors
Sign Up to like & getrecommendations! Published in 2019 at "Investigational New Drugs"
DOI: 10.1007/s10637-019-00768-6
Abstract: SummaryPurpose Brentuximab vedotin (BV) is an anti-CD30 antibody-drug conjugate used in the treatment of several types of lymphomas. Expression of the target antigen has also been reported on a variety of malignant tumors of nonlymphoid… read more here.
Keywords: solid tumors; study; phase open; open label ... See more keywords
Randomized Prospective Open Label Study Shows No Impact on Clinical Outcome of Adding Losartan to Hospitalized COVID-19 Patients with Mild Hypoxemia
Sign Up to like & getrecommendations! Published in 2021 at "Infectious Diseases and Therapy"
DOI: 10.1007/s40121-021-00453-3
Abstract: Despite considerable scientific debate, there have been no prospective clinical studies on the effects of angiotensin II receptor blockers (ARBs) on the course of COVID-19 infection. Losartan is the ARB that was chosen to be… read more here.
Keywords: hospitalized covid; study; randomized prospective; open label ... See more keywords
Open-label study (ARIDO) evaluating long-term safety of topical glycopyrronium tosylate in patients with primary axillary hyperhidrosis
Sign Up to like & getrecommendations! Published in 2018 at "Journal of The American Academy of Dermatology"
DOI: 10.1016/j.jaad.2018.05.847
Abstract: 1Saint Louis University, St. Louis, MO; 2UTHealth McGovern Medical School, Houston, TX; 3Charité–Universitätsmedizin Berlin, Berlin, Germany; 4Premier Clinical Research, Spokane, WA; 5Shideler Dermatology and Skin Care Center, Carmel, IN; 6George Washington University School of Medicine,… read more here.
Keywords: dermatology; study arido; open label; evaluating long ... See more keywords
An open-label study of the tolerability and potential efficacy of memantine for treating refractory chronic cough
Sign Up to like & getrecommendations! Published in 2021 at "ERJ Open Research"
DOI: 10.1183/23120541.00447-2021
Abstract: Refractory chronic cough (RCC) is defined as cough lasting longer than 8 weeks either in the absence of an identifiable underlying cause or that remains resistant to treating any potential underlying causes [1]. Affected patients have… read more here.
Keywords: cough; open label; label study; chronic cough ... See more keywords
INDUCE-1: A phase I open-label study of GSK3359609, an ICOS agonist antibody, administered alone and in combination with pembrolizumab in patients with advanced solid tumors.
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.15_suppl.tps3113
Abstract: TPS3113Background: Inducible T cell Co-Stimulator (ICOS), a member of the CD28/B7/CTLA-4 receptor superfamily expressed on T cells after engagement with cognate antigen and activation, provides a c... read more here.
Keywords: gsk3359609 icos; study gsk3359609; phase open; induce phase ... See more keywords
A phase II, open label study of tucatinib (ONT-380) combined with trastuzumab in patients with HER2+ metastatic colorectal cancer (mCRC)(MOUNTAINEER).
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.15_suppl.tps3624
Abstract: TPS3624Background: To improve survival for patients with mCRC, efforts are needed to identify and treat actionable genomic alterations. HER2 is amplified in approximately 5-8% of patients with KRAS... read more here.
Keywords: tucatinib ont; study tucatinib; phase open; ont 380 ... See more keywords
A phase 2, open-label study of the combination of spartalizumab (PDR001) and LAG525 for patients with advanced solid tumors and hematologic malignancies.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.tps2616
Abstract: TPS2616Background: Spartalizumab is an immunoglobulin G4 humanized monoclonal antibody that binds with subnanomolar affinity to PD-1. LAG525 is an immunoglobulin G4 humanized monoclonal antibody th... read more here.
Keywords: combination spartalizumab; study combination; lag525; phase open ... See more keywords
A phase 3, randomized, open-label study of nivolumab combined with cabozantinib vs sunitinib in patients with previously untreated advanced or metastatic renal cell carcinoma (RCC; CheckMate 9ER).
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.tps4598
Abstract: TPS4598Background: Over the past decade, treatment options for advanced RCC have evolved to include multiple agents targeting the vascular endothelial growth factor (VEGF) pathway. In addition, the... read more here.
Keywords: randomized open; phase randomized; nivolumab combined; open label ... See more keywords
A phase II, multicenter, open-label study of trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): DESTINY-CRC01.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2020.38.15_suppl.4000
Abstract: 4000Background: T-DXd is an antibody-drug conjugate composed of an anti-HER2 antibody, cleavable tetrapeptide-based linker, and topoisomerase I inhibitor payload. Early studies have shown promising... read more here.
Keywords: trastuzumab deruxtecan; study trastuzumab; phase multicenter; open label ... See more keywords
A phase Ib/II, open-label study of tivozanib in combination with durvalumab in subjects with untreated advanced hepatocellular carcinoma.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2020.38.15_suppl.e16599
Abstract: e16599Background: VEGFR TKIs and checkpoint inhibitors are current standards of care in HCC as single agents, however treatment options are limited, and significant unmet need remains. A recent ph3... read more here.
Keywords: phase open; tivozanib combination; study tivozanib; combination durvalumab ... See more keywords